CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 1 of 44 
 
 
 
 
Prospective, Multicenter Study for the Evaluation of 
Safety and Performance of the Interscope EndoRotor® 
Endoscopic Mucosal Resection System for the 
Removal of Alimentary Tract Mucosa in the Colon  
 
Protocol Number:  CLIN 0001 -US 
Revision A 
19 April  2019 
 
Sponsor:  
Interscope,  Inc.  
[ADDRESS_1215775]  
Whitinsville , [LOCATION_005], [LOCATION_003] [ZIP_CODE]  
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  DO NOT COPY  
This study protocol contains confidential information for use by [CONTACT_870748]. It should be held confidential and maintained in a secure location. It should not be co pi[INVESTIGATOR_260793] .
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 2 of 44 Investigator’s Protoco l Signature [CONTACT_168882]:  
 PROSPECTIVE MULTICENTER STUDY FOR THE EVALUATION OF 
SAFETY AND PERFORMANCE OF THE INTERSCOPE ENDOROTOR® 
ENDOSCOPIC MUCOSAL RESECTION SYSTEM FOR THE REMOVAL OF 
ALIMENTARY TRACT MUCOSA IN THE COLON  
 
PROTOCOL 
NUMBER:  CLIN 000 1-US, Revision A 
 
STUDY CENTER:  _____________________________________________  
 (Print name [CONTACT_205425])  
 
By [CONTACT_31300], I confirm that I will not enroll subjects in this study until IR B approval has 
been obtained at my site.  I have read this protocol and agree to adhere to t he protocol and study 
requirements.  I will discuss this protocol and all related study material with the research team at 
my institution and ensure that they are fully informed regarding the study requirements and use 
of the EndoRotor® device.  I will als o ensure that the study is conducted in accordance with all 
applicable standards and regulations; including, but not limited to, the Declaration of Helsinki, 
Good Clinical Practices (GCP), FDA Regulations, the Sponsor, the IRB and any other 
applicable loca l or national requirements.  
 
 
 
___________________________________________________________________  
Principal Investigator  – Print ed Name  
 
 
___________________________________________________________________  
Principal Investigator – Signature  
 
 
________________ _______  
Date  
 
 
  
 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 3 of 44 TABLE OF CONTENTS  
 
1.0 INTRODUCTION AND BAC KGROUND  ................................ ................................ ... 12 
1.1 Introduction  ................................ ................................ ................................ ....................  12 
1.2 Background  ................................ ................................ ................................ ....................  12 
1.2 Background  ................................ ................................ ................................ ....................  12 
1.2.1  Gastrointestinal Polyps  ................................ ................................ ...........................  12 
1.3 Literature Summary ................................ ................................ ................................ ........  14 
1.3.1  Rectum/Colon Polyps  ................................ ................................ .............................  14 
1.3.2  Summary  ................................ ................................ ................................ .................  15 
1.4 Report of Prior Investigations  ................................ ................................ ........................  15 
1.4.1  Summary of Prior Human Clinical Use  ................................ ................................ .. 15 
1.4.2  Summary of Pre-Clinical (Animal) Testing  ................................ ............................  [ADDRESS_1215776] -MARKET  STUDY P LAN  ................................ ................................ ..................  19 
3.1 Study Objective  ................................ ................................ ................................ ..............  19 
3.1.1  Study Design  ................................ ................................ ................................ ...........  19 
3.1.2  Enrollment ................................ ................................ ................................ ...............  19 
3.1.3  Study Population  ................................ ................................ ................................ ..... 19 
3.2 Study Duration & Follow -Up ................................ ................................ .........................  [ADDRESS_1215777] Enrollment and Withdrawal  ................................ ................................ ..............  22 
5.4 Anticipated Total E nrollment  ................................ ................................ .........................  23 
5.5 Schedule of Events  ................................ ................................ ................................ .........  23 
5.6 Baselin e Evaluation, not greater than 14 days prior to the Index Procedure  .................  23 
5.6.1  Baseline Demographics and Relevant Medical History  ................................ .........  23 
5.7 Index Procedure ................................ ................................ ................................ ..............  24 
5.7.1  Index Procedure Details  ................................ ................................ ..........................  25 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 4 of 44 5.8 90-Day Follow -Up (+/- 14 days)  ................................ ................................ ....................  26 
6.0 ADVERSE EVENTS  ................................ ................................ ................................ ....... 26 
6.1 Adverse Event (AE)  ................................ ................................ ................................ ....... 27 
6.1.1  Serious Adverse Event (SAE)  ................................ ................................ .................  28 
A serious adverse event (SAE) is defined as an adverse event that : ................................ ..... 28 
• Is life threatening or fatal;  ................................ ................................ ..............................  28 
• Results  in permanent impairment of a body structure or function;  ................................  28 
• Results in congenital anomalies/birth defects  ................................ ................................  28 
• Requires or prolongs h ospi[INVESTIGATOR_059]; or  ................................ ................................ ........  28 
• Requires medical or surgical intervention to preclude permanent impairment of a body 
function or permanent damage to a body structure.  ................................ ..............................  28 
6.1.2  Unanticipated Adverse Device Effects (UADE)  ................................ ....................  29 
6.2 Adverse Event Reporting Requirements  ................................ ................................ ........  29 
6.2.1  General  Reporting Requirements  ................................ ................................ ............  29 
6.2.2  Reporting Requirements for Serious Adverse Events  ................................ ............  30 
6.2.3  Treatment Failure & Device Malfunction Repor ting................................ ..............  30 
7.0 RISK/BENEFIT ASSESSM ENT  ................................ ................................ ....................  31 
7.1.1  Risk Minimization  ................................ ................................ ................................ .. 31 
7.2 Justif ication for the Study  ................................ ................................ ..............................  32 
7.4 Incentives (if applicable)  ................................ ................................ ................................  32 
8.0 STATISTICAL ANALYSIS  PLAN  ................................ ................................ ...............  32 
8.1 Population Demographics  ................................ ................................ ..............................  32 
8.2 Analysis Populations  ................................ ................................ ................................ ...... 32 
8.3 Interim Analysis  ................................ ................................ ................................ .............  33 
8.4 Primary Endpoint Analysis  ................................ ................................ ............................  33 
8.5 Safety Analysis  ................................ ................................ ................................ ...............  33 
8.6 Secondary Endpoint Analysis  ................................ ................................ ........................  33 
8.7 Site Poolability  ................................ ................................ ................................ ...............  33 
8.8 Sample Size  ................................ ................................ ................................ ....................  33 
8.9 Handling of Missing Data  ................................ ................................ ..............................  34 
9.0 INVESTIGATOR RESPONS IBILITIES, RECORDS &  REPORTS  ........................  [ADDRESS_1215778] (IRB)  Approval  ................................ ................................ . 34 
9.2 Withdrawal of Approval ................................ ................................ ................................ . 34 
9.4 Informed Consent  ................................ ................................ ................................ ...........  35 
9.5 Clinical Data Collection  ................................ ................................ ................................ . 35 
9.6 Device Accountability  ................................ ................................ ................................ .... 35 
9.7 Investigator Reports  ................................ ................................ ................................ ....... 35 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 5 of 44 9.7.1  Serious Adverse Events (SAEs) & Unanticipated Adverse De vice Effects (UADEs)
 35 
9.7.2  Device Performance Issues  ................................ ................................ .....................  36 
9.7.3  Deviations from the Study Plan  ................................ ................................ ..............  36 
9.7.4  Investigator Final Report  ................................ ................................ ........................  36 
Table 2:  Investigator Report Submission Summary  ................................ ................................ .... 36 
10.0  SPONSOR RESPONSIBILI TIES ................................ ................................ ..................  37 
10.1  Selection of Clinical Sites & Investigators  ................................ ................................ .... 37 
10.2  Investigator & Staff Training  ................................ ................................ .........................  37 
10.3  Monitoring  ................................ ................................ ................................ ......................  37 
10.4  On-Site Audits  ................................ ................................ ................................ ................  38 
10.5  Records & Record Retention  ................................ ................................ .........................  [ADDRESS_1215779] Expenses  ................................ ................................ .......................  39 
11.0  QUALITY ASSURANCE & ETHICAL STANDARDS  ................................ ..............  39 
11.1  Data Monitor ing Committee for Adverse Event Adjudication  ................................ ...... 39 
11.2  Compliance Monitoring & Study Termination  ................................ ..............................  [ADDRESS_1215780] OF RELEVANT DEF INITIONS  ................................ ................................ .........  41 
13.0  BIBLIOGRAPHY  ................................ ................................ ................................ ............  43 
 
APPENDIX 1 – SCHEDULE OF EVENTS   
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215781] of Abbreviations  
AE Adverse Event  
AR Adverse Reaction  
CA Compete nt Authority  
CIP Clinical Investigational Plan  
CV Curriculum Vitae  
DMC  Data Monitoring Committee  
EndoRotor® The EndoRotor® is a powered tissue resection system produced by [CONTACT_695731], Inc . 
of Whitinsville , MA, [LOCATION_003].  
EU European Unio n 
GCP  Good Clinical Practice  
IB Investigator’s Brochure  
IC Informed Consent  
IRB Institutional  Review Board  
MREC  Medical research ethi cs committee   
(S)AE  (Serious) Adverse Event  
SPC Summary of Product Characteristics  
Sponsor  The sp onsor is the party that commissions the organisation or performance of the 
research, for example a pharmaceutical  or medical device company  
company, acade mic hospi[INVESTIGATOR_307], scientific organisation or investigator. A party that 
provides funding for a study but does not commission it is n ot regarded as the 
sponsor, but referred to as a subsidising party.  WIRB  Western Institutional  Review Board  
 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 7 of 44 Protocol Summary  
PROTOCOL 
NUMBER  CLIN 0001 -US / Revisi on A 
Study Title:  Prospective, Multicente r Study for the Evaluation of Safety and 
Performance of the Interscope EndoRotor® Endoscopic Mucosal 
Resection System for the Removal of Alimentary Tract Mucosa in the 
Colon  
Study Objective:  To collect data in su pport of the safety and performance of the  Interscope 
EndoRotor® Endoscopic Mucosal Resection System on a post -market 
basis. The study will confirm  that the EndoRotor® resections are safe and 
effective.  
Study Device:  Interscope EndoRotor® Endoscopic Muco sal Resection System  
Indication for Use:  The EndoRotor® is intended for use in endoscopic procedures by a 
trained gastroenterologist to resect and remove tissue, not intended for 
biopsy, of the gastrointestinal (GI) system including post -endoscopic 
mucos al resection (EMR) tissue persistence with a scarred base and 
residual tissue from the peripheral margins following EMR.  
Regulatory Status:  The Interscope EndoRotor® Mucosal Resection System is a cleared Class  
II med ical device per 21CFR 807.92 and 21 CF R 884.1690 under 510( K) 
K181127.    
The EndoRotor is also approved under MDD 93/42/EEC on Medical 
Devices Annex II, excluding Section 4.  The device bears the CE Mark 
as a Class IIa under Rule 5 o f Annex IX  where it  is indicated for 
excision/ resection of  aliment ary tract lesions including pan necroses via 
direct endoscopic necrosectomy  (CE 613797).   
 
According to the CFR and MDD the EndoRotor® is not an 
investigational produc t.  The study does not include any non -standa rd of 
care assessments; therefore, the  study is classified as a non -interventional 
(or observational) study.  
 
The device has been designed and is manufactured under the control of 
the Interscope, Inc . Quality Management System. Interscope, Inc . is ISO 
[ZIP_CODE] certified  (FM [ZIP_CODE]) .   
Study Desi gn: Post-market, prospective, non -randomized, multi -center study for the 
treatment of subjects with the need for resection of  recurrent flat or 
sessile  colorectal lesions  where EndoRotor is the primary resection 
modali ty of persistent adenoma with a scarre d base.  
Enrollment:  Total enrollment is at least 60 evaluable  subjects at  up to  15 clinical sites 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215782] Population:  Adult subjects aged ≥18 to ≤[ADDRESS_1215783] one or more recurrent 
flat or sessile  rectal/colon muc osal polyps  measuring up to  6 cm in 
diameter and/or length . 
Estimated Study 
Duration:  First subject enrolled:         
Last subject enrolled:     
Study completion (final 90 -day visit, closeout visit):   
   June 2019 
Dece mber  2019 
June 2020  
Primary Endpoints : Primary Effectiveness Endpoint (Performance) : 
Technical Success, defined as the ability of the En doRotor device to 
resect recurrent  flat or sessile  colorectal lesion s without concomitant use 
of other resection modali ties for mucosectomy and no definitely  or 
probably device -related serious adverse events (SAEs) throughout the 
90-day follow -up perio d. 
 
Primary Safety Endpoint :  
Assessment of Serious Adverse Events (incidence, relationship to device 
and severity) at inde x procedure and at [ADDRESS_1215784] -proce dure. 
Secondary Endpoints:  1. Completeness, in percentage, of resection based on endoscopy fil m 
and/or photographs and in addition to diagnostic assessment of 
specimen graded by [CONTACT_870749].  
2. Presen ce of colon stenosis based on endoscop y film and/or 
photographs.  
3. Rate of persistence of disease at the location of resection at 9 0 days.  
4. Histologic assessment of the diagnostic value of the collected 
specimens.     
Primary Analysis:  The Per Protocol  (PP) analysis population will be the primary 
effectiveness analysis population.  
Inclusion Criteria:  1. Subjects aged ≥18 to ≤ [ADDRESS_1215785] one recurrent flat or sessile  colorectal lesion  measuring  up to  
6 cm in diameter and/or length . 
3. Presence of  recurrent  flat or sessile  lesion where the EndoRotor® 
may be used to resect recurrent neoplasia .  
4. Favorabl e anatomy that allows the inve stigator to access the lesion.  
5. Subject is able and willing to comply with site standard medical 
follow -up, including the [ADDRESS_1215786] has been informed of the nature of the study, agrees to 
participate and has signed the consent form. 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 9 of 44 Exclusion Criteria:  1. Inability to give informed consent.  
2. Subject age is ˂18 years of age or >85 years of age.  
3. Presence of a lesion that represents cancer or has a high chance of 
harboring submucosal invasive cancer.  
4. Presence of synchronous lesions intended for resection that would 
require  use of a concomitant re section modality   
5. Medical reasons the procedure cannot be performed (i.e. labile 
blood pressure, anticoagulation laboratory levels that are too high 
and risk excessive bleeding, systemic infection, etc.) 
6. Active antiplatelet therapy (Plavix®, 325mg aspi[INVESTIGATOR_119457]) – 
patient off treatment for < [ADDRESS_1215787] at an unacceptable 
surgical risk (e.g.,  severe chronic obstructive pulmonary disease, 
hepatic failure, cardiac disease, autoimmune disorders or conditions 
of severe immunosuppression).  
10. Any clinical evidence that the investigator feels woul d place the 
subject at increased risk with the deploymen t of the device.  
11. Subject is participating in another study of a device, medication, 
biologic, or other agent within [ADDRESS_1215788] -treatment.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215789]:   
Sponsor:  Interscope, Inc.  
Address:  [ADDRESS_1215790] Person: Jeffery Ryan, Jr., President and CEO  
Telephone:  +1 -[PHONE_14471]  
Email:  [EMAIL_13294]   
Study Principal 
Investigato r 
 
(Refer to Appendix [ADDRESS_1215791])  [CONTACT_870781], MD FACG  
Address:  Università Cattolica del Sacro Cuore, Instituto di Clinica 
Chirurgica, Largo A. Gemelli, 8 - [ZIP_CODE] Roma , Italy  
Mobile: + 39 06 -35511515  
Fax: + 39 06 -30156581  
Email:  [EMAIL_16503]  
Device Technical 
Support  Interscope, Inc .  
Jeffery Ryan, President and CEO  
Mobile: + [PHONE_18043]  
Normal hours: Mon -Sat 7am to 6pm EST  
Emergencies (24 hours a day)  
jeffery.ryan @interscopemed.com  
Study Management 
(Clinical Research 
Organization):  Alvamed, Inc.  
Eric Bannon , VP, Regulatory and Clinical Affairs  
Address:  [ADDRESS_1215792]  
Needham, [LOCATION_005], [LOCATION_003] [ZIP_CODE]  
Telephone:  +1 -[PHONE_18044]  
Cell:  +[PHONE_18045]   
Email: ebannon@alva med.com    
[LOCATION_003] Monitoring:  Patricia Co llins, RN, Clinical Research Associate  
Address:  [ADDRESS_1215793]  
Needham, [LOCATION_005], [LOCATION_003] [ZIP_CODE]  
Telephone:  +[PHONE_18046]  
Email: [EMAIL_16504]  
Europe Monitoring:  Italy:   
Giovanni Castegnaro  
Address(es) 45/1, Via Matteotti, [ZIP_CODE], Zola Predosa, BO (Italy)  
Telephone [PHONE_18049]  
Mobile: +39 [PHONE_18047]  
E-mail: giovanni.ca [EMAIL_16505]  
 
[LOCATION_009]:   
Laurence Van Meenen  
Address: LVM ARC – Cavaniè, [ZIP_CODE] Cahors   [LOCATION_009]  
Mobile: +33 (0) 6 84 24 89 34  
Email: lvm@lvm -arc.com   
 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 11 of 44  
[LOCATION_013]:   
Thomas Magyar, PhD  
Address: Neulandstrasse 42, 4 7807 Krefeld, [LOCATION_013]  
Telephone: +49 (0)2151 3612486  
Mobile: [PHONE_18050]  
Fax: [PHONE_18051]  
E-mail: [EMAIL_16506]  
Safety Reporting:  Interscope, Inc . 
c/o Alvamed, Inc.  
Eric Bannon , Acting Director , Regulatory and Clinical Affairs  
Address:  [ADDRESS_1215794], Needham, MA [ZIP_CODE]  
Cell:  +[PHONE_18045]   
Email: ebannon@alva med.com    
Safety Monitoring:  Independent Physician Adjudicator  
Name [CONTACT_870779]: TBD  
Europe Pathology 
Core Lab:  Independent Patholog ist 
[CONTACT_870782]:  Institute of Pathology, Ruhr -University Bochum  
Buerkle -de-la-Camp -Platz 1, [ZIP_CODE] Bochum, [LOCATION_013]  
Telephone:  +49 (0)234 -302-4800  
E-mail:  [EMAIL_16507]  
andrea.tannapfel@pathologie -bochum.de  
Data Coordinating 
Center:  Alvamed, Inc.  
Kerry Beckett, Sr. Clinical  Research Associate  
Address: [ADDRESS_1215795], Needham, MA [ZIP_CODE]  
Telephone:  +1 -[PHONE_18048]  
Fax:  +1 (617) 249 -0955  
Email:  [EMAIL_16508]  
 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 12 of 44 1.0  INTRODUCTION AND BAC KGROUND  
1.1 Introduction  
The EndoRotor® Endoscopic Mucosal Resection System is a non-thermal  mechanical 
endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic 
or pre -malignant tissue removal by [CONTACT_870750].  The 
EndoRotor® System performs both tis sue resection  and extraction  with a single device. The 
EndoRotor® System allows a gastroenterologist to access and remove polypoid or abnormal 
mucosa through an endoscope’s instrument biopsy channel without removing and re -inserting 
the scop e and without having to use multiple instruments. A motorized rotating cutting tool 
driven by [CONTACT_695720]. Because the system 
automatically suctions and cuts about [ADDRESS_1215796] methods.  
 
Although the EndoRotor® was designed to be used within the esophagus, st omach, small and 
large intestine, in this study, Interscope will evaluate the use of the EndoRotor® to resect 
diseased colorectal mucosa only.  
• In this study, recurrent flat or sessile  lesions up to 6 cm in diameter and/or length in the 
appropriate patient will be removed using the EndoRotor®.  
• Various parameters, such as bleeding requiring intervention, perforation, speed of 
resection, and adequacy of the specimens to produce a diagnosis will be assessed.  
Routine endoscopic surveillance at  [ADDRESS_1215797] is the system of organs that is respons ible for consumin g and 
digesting foodstuffs, absorbing nutrients and expelling waste. In humans, it consists of the 
esophagus, stomach, small intestine (duodenum, jejunum & ileum) and large intestine (cecum, 
colon, rectum & anal canal), with the upper GI t ract comprising t he mouth to the duodenum and 
the lower GI tract comprising the cecum to the anus. The structure of the gastrointestinal wall is 
relatively consistent throughout the length of the tract and involves four layers, the mucosa, 
submucosa, muscu laris propria, an d serosa or adventitia. The mucosa is the innermost layer that 
surrounds the lumen and is exposed to the contents of the tract. It is itself composed of 3 layers: 
epi[INVESTIGATOR_2130], lamina propria, and muscularis mucosa, and is highly specialized  in each organ of  
the GI tract. The submucosa consists of connective tissue and supplies blood vessels, lymphatic 
vessels, and nerves to the mucosa. The muscularis propria, also known as the muscularis 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215798] polyps are largely asymptomatic and despi[INVESTIGATOR_870734], if left untreated certain types of polyps can become malignant and 
develop into  cancer.  
 
Polyps can be classified by [CONTACT_870751]:  
 
• Non-malignant potential polyps. Hyperplastic poly ps are the most common type of 
polyp in the colon, accounting for 90% of all polyps detected. Hyperplastic, 
harmartomatous/juvenile and inflammatory polyps are also considered to have no 
malignant  potential.  
• Low/Mo derate -malignant potential polyps. Although only 5% of adenomas evolve to 
cancer, it is accepted that the majority of carcinomas evolve from adenomatous polyps.  
Adenomatous polyps should be considered as precursors to carcinomas and shoul d be 
removed when ever possible.  
• High -malignant potential polyps. Serrated -adenoma polyps have recently been 
identified and display features of both non -malignant and moderate -malignant potential  
polyps.  
 
In addition, polyps can also be classified by [CONTACT_870752] : 
 
• Sessile polyps are broad -based without a connecting stalk. They arise directly from the 
mucosal layer and account for approximately 50% of all  polyps.  
• Pedunculated  polyps  are defined  by a head  connected  to a stalk  or pedicle  and 
account  for approximatel y 5% of all polyps.  
• Flat polyps are non -protruding or non -raised lesions with a height of less than one -half 
the diameter of the  lesion.  
• Depressed polyps are very uncommon and are particularly likely to harbor high - grade 
dysplasia or be m alignant, even wh en small.  
 
Although the majority of polyps are non -malignant, it is known that the risk of malignancy 
increases with polyp size, with polyps < 10 mm having < 1% risk of cancer, polyps of 10 mm 
having a 10% risk of cancer and polyps of 20 m m having a greate r than 10% risk of cancer. It is 
also understood that a polyp of < 1 cm takes approximately 10 years to transform into invasive 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215799] endoscopi[INVESTIGATOR_897]. 
The scarring can be caused by  [CONTACT_870753], previous deep biopsies, or tattoos 
placed too closely. These polyps often do not lift and can be impossible to sna re even when stif f 
snares are used. Endoscopic submucosal dissection (ESD) and knife -assisted resection (KAR) 
are techniques that have been shown effective in the management of scarred polyps, however 
these techniques have not been widely adopted in the We st. Argon plasma coagulation has been 
more commonly used to ablate adenomatous tissue in scarred polyps but this technique does not 
allow for the histological assessment of the scarred polyp and is less effective than ESD.  The 
EndoRotor provides a techniqu e whereby [CONTACT_870754].  
 
1.3 Literature Summary  
1.3.1 Rectum/Colon Polyps  
Although most colon polyps are small (90% are less than 1cm) and never progress to ca ncer(1,2), 
the la rger polyps have a higher chance of harboring advanced histology and even cancer.  Larger 
polyps and sessile polyps present the endoscopi[INVESTIGATOR_870735] -suited to add ress.  EMR and En doscopic Submucosal 
Dissection (ESD) are the main advanced techniques used to remove larger lesions by 
[CONTACT_870755][INVESTIGATOR_11437].  When comparing the two, there are some striking differences 
between them.  EMR involves the pi[INVESTIGATOR_870736]’s skill and the size of the lesion.  EMR is more widespread and is 
easier to learn (30 -40 cases) than ESD that requires from 60 to 80 cases to become proficient.  
ESD requires the lif ting of the lesio n with fluid and the excision of the lesion in one pi[INVESTIGATOR_13959].  This 
meticulous resection requires much more time (45 to 90 minutes) but offers a surgical specimen 
that can be oriented and evaluated for margins and depth of penetration as one c omplete sample.  
ESD is much more commonly performed in Eastern Asia (Japan) than in Europe or the United 
States.  
O’Brien, Michael J, et. al. reported results of an analysis encompassing 8401 person -years of 
follow -up evaluation(3). AT and AR measures of a denoma flatness w ere 95% concordant. By [CONTACT_870756], flat adenomas (n 474) represented 27% of all baseline adenomas. Flat adenomas 
identified in the National Polyp Study cohort at baseline were not associated with a higher risk 
for high -grade dysplasia initially, or for  advanced adenomas at surveillance.  Flat adenomas were 
found to be no more likely to exhibit high -grade dysplasia than sessile (polypoid) or 
pedunculated adenomas.  
At the present time, there are 2clinical literature reports specific to th e EndoRotor® System  
dealing with recurrent adenoma in a single center and Barret’s esophagus respectively .  Based on 
clinical and extensive pre -clinical \results in a post -market setting, t he EndoRotor® has several 
inherent advantages over EMR and ESD  techniques in the removal of scarred lesions . It is cost -
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215800] more precision with resections and still allows for histolo gical 
evaluation o f the tissue  as opposed to thermal ablative techniques .  The EndoRotor® potentially 
presents an opportunity to evaluate an instrument that could impact incomplete resection  and 
removal of lesions with a scarred base . According to Knabe, e t al, a substantia l (31.69%) 
proportion of pi[INVESTIGATOR_870737]-resection scars harbor residual occult neoplasia that may cause late recurrences(4).  The 
authors reported on a study of 243 consec utive patients wit h 252 adenomas that were followed 
using a standardized protocol after complete endoscopic resection.  After endoscopic treatment, 
the patients received standardized follow -up examinations after 3 –[ADDRESS_1215801] polypectom y scar was re -examined, assessed for residual neoplasia, and biopsied at each 
follow -up colonoscopy.  Evident residual neoplasia was noted after 3 –6 months in the majority 
of lesions (58 of 183 lesions totaling 31.69%). After 12 months, 126 LNLs were exami ned, with 
19 late  recurrences (16.37%). Twenty -one (6.5%) post  polypectomy scars were not detected 
during 321 surveillance examinations. Biopsy evidence of residual/recurrent lesions was found in 
16 of 228 macroscopi[INVESTIGATOR_870738] (7% ). All residual adenomas were 
treated using ER and/or argon plasma coagulation.   The use of Argon plasma provides no 
histologic specimen in the management of post -EMR persistent lesions with a scarred base  and 
thus precludes timely assessment of the effica cy of the  resect ion.  
1.3.2 Summary  
Following a review of the published literature, the main complications found to be associated 
with polypectomy were  bleeding/hemorrhage, perforation, and post -polypectomy syndrome, 
which are reported to occur in 0 -10.8%, 0 -2.3%, and 0.14 -3.7%  of patients, respectively. Deaths 
were reported in only 2 studies, at a rate of 0.01% and 0.1%. The greatest risk factor for an 
adverse event is associated with increasing polyp size. In terms of performing polypectomy, the 
most commonly referenced outcom e measures were  completeness of polyp removal or 
recurrence, with a range from 73 -100% and 1.4 -24% respectively, in the published literature.  
Supporting evidence of a 3 -month follow up visit, as is indicated in the EndoRotor colon study, 
was also reported  in the medical literature.  Additionally, it was determined that flat adenomas 
are no more likely to exhibit high -grade dysplasia than sessile (polypoid) or pedunculated 
adenomas thereby  [CONTACT_870757] , and therefore   provides 
the rationale for  the inclusion criteria in the EndoRotor colon study.  
1.4 Report of Prior Investigations  
1.4.1 Summary of Prior Human Clinical Use 
The EndoRoto r® has been used to resect diseased colorectal mucosa in humans on a post -market basis 
commercially in over 400 procedures (100 walled off necrosis, 70 Barrett’s Esophagus and over [ADDRESS_1215802] been  3 multi -center prospective clinical 
studies in approximately 40 patients in colon resection and 47 patients  in Barrett’s Esophagus , and 30 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 16 of 44 patients in removal of walled off necrosis  .  In the Barrett’s series  2 cases of delayed bleed ing occurred 
and were successf ully controlled  endoscopi[INVESTIGATOR_897].  One colon perforation  was observed and closed 
endoscopi[INVESTIGATOR_870739] -pathological assessment provides  pathologists  with information 
over ablative techniques that era dicate pathology .  EndoRotor clinical lit erature includes t wo peer review 
publication s in addition to 3  submission s, one in colon , one in Barrett’s Esophagus  and one in walled off 
necrosis  are under rev iew.   
1.4.2  Summary of Pre-Clinical (Animal) Testing  
Animal testing of the EndoRotor was conducted to evaluate the overall safety and performance 
of the device in an animal model.  A summary of the study is presented below.  
The objectives of this study were to evaluate the EndoRotor system for performance of tissue 
resection in an animal model, with res pect to safety:  
• Assessment of tissue response acutely and at [ADDRESS_1215803] 
light microscopy  
• Clinical assessment of bleeding at sites of resection  
The animal study was conducted under Good Laboratory Practice (GLP) guidelines . Six 
Yorkshire swine were utilized. Over 120 resections were completed between the colon, stomach, 
and esophagus, and distributed across different sizes. The studies were conducted at CBSET 
Lexington, [LOCATION_005], [LOCATION_003] as part of a Good Lab Practices (GL P) protocol, as well as for a 
preliminary research project in [LOCATION_013] at the Institut für Nutztiergenetik, Mariensee, Friedrich -
Loeffler -Institut (FLI) Bundesforschungsinstitut für Tiergesundheitusing in live pi[INVESTIGATOR_14107](5). 
Perforation and bleeding were the main  safety criteria assessed . Other major endpoints were 
device performance/usability and histopathology. Perforation was noted in 2 (1.6%) of the 
resection sites, comparing favorably to the published rate of 2.3%. Bleeding was graded as mild 
(resolves in 2 m inutes or less without intervention) in 79.5% of sites, as moderate bleeding 
(resolves in greater than 2 minutes without intervention) in 19.7% of sites, and one site (0.8% 
of sites) as severe bleeding (requires intervention to resolve the bleeding) which resolved after  
epi[INVESTIGATOR_130630]. The bleeding rate that required intervention compares favorably to 
the rates for current interventional techniques published in the literature (0.8% vs. 1 -16%). The 
study pathologist indicated that use of the End oRotor® System for mucosal tissue resection in 
the porcine esophagus, stomach and colon was  associated with favorable and clinically 
acceptable tissue responses. The EndoRotor® System received passing evaluation for all 
performance and intended use criter ia by [CONTACT_695728].  
Review of multiple techniques for the removal of polyps from the gastrointestinal tract suggests 
that the EndoRotor® System (with or without injection) will not introduce any new or 
unrecognized sa fety risks and will have a favorable risk/benefit profile.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 17 of 44 1.4.3 Summary of Design Verification and Validation Testing  
The Interscope EndoRotor® System has undergone extensive design verification and validation testing 
consistent with the Essential Requirements of the Medical Device Directive, applicable ISO standards, 
and applicable test methods.  The EndoRotor® has been tested and has successfully passed the acceptance 
criteria for the following:  
• Biocompatibility  
• Functional Performance  
• Sterilization  
• Shelf Life  
• Electromagnetic Compatibility  
• Software Verification  
• Usability  
• Package Integrity  
2.0 DEVICE DESCRIPTION  
The EndoRotor® System performs both tissue dissection and resection with a single device. The 
EndoRotor® System allows a gastroenterologist to access and rem ove polypoid or abnormal 
mucosa through an endoscope’s instrument biopsy channel without removing and re -inserting 
the scope and without having to use multiple instruments. A motorized, rotating, cutting tool 
driven by [CONTACT_695720]. Resected tissue is 
immediately aspi[INVESTIGATOR_870740] a micron filter. Tissue 
collected on the filters can be used for pathological examination using standard methods.  Th e 
device is not user pr ogrammable - it utilizes an off the shelf Maxon® electric motor built in the 
console and cannot be adjusted by [CONTACT_870758]® System is comprise d of the following core components:  
• EndoRotor Console®: The system control unit housing the motor driv e, peristaltic pump 
and pi[INVESTIGATOR_870741], irrigation, and vacuum regulation respectively. 
(Figure  1). 
• EndoRotor Foot Control®: Activates/deactivates cutter rotation/lavage and aspi[INVESTIGATOR_1516]  
(suction).  
• EndoRotor Catheter®: The outer jacket of th e cutter catheter serves as the delivery 
vehicle for the irrigation fluid that flows between the inner wall of the braid and outer 
wall of the torque coil. It also allows for outer cutter repositioning. The outer braided 
sheath is attached to the distal cu tter at the end of the catheter. The torque coil transmits 
internal rotation to the inner cutter and is sealed with a shrink sleeve to contain 
aspi[INVESTIGATOR_1516]. The rotation motion cuts tissue, which is simultaneously removed from the 
resection site by [CONTACT_189175]. The distal ends of the lavage and aspi[INVESTIGATOR_695704] (Figures  2-4). 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 18 of 44 
• Collection Device: EndoRotor Specimen Trap® with pre -loaded micron filter. This 
custom trap is designed specifically to capture EndoRotor® specimen.  
• Polyp Filter: The EndoRotor Filter Set® includes 200 replacement filters that can be 
exchanged and placed within the EndoRotor Specimen Trap® to ensure collection of 
resected  tissue.  
 
 
  
 
Figure 1.  EndoRotor Console® Figure 2. Tubing and Resecting 
Cutter Components  
 
 
 
 
 
 
 
 
Figure 3.  Disposable Resecting 
Cutter   
 
 
 
 
 
 
 
Figure 4. Drawing of Resecting 
Cutter Deployed in Endoscope 
Working Channel   
Figure 3.  Disposable Resecting Cutter  Figure 4.  Drawing of Resecting Cutter 
Deployed in Endoscope Working Channel 
2.1 Indication for Use  
The EndoRotor® is intended for use in endoscopic procedures by a trained gastroenterologist to 
resect and remove tissue, not intended for biopsy, of the gastrointestinal (GI) system including 
post-endoscopic mucosal resection (EM R) tissue persistence with a scarred base and residual 
tissue from the peripheral margins following EMR.  The EndoRotor® System resects and 
removes mucosal tissue simultaneously thr ough a catheter inserted into the working channel of a 
flexible endoscope.  The EndoRotor® System will be used for removal of mucosal /sub-mucosal  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 19 of 44 tissue in the colon  within the 510(k) clearance  indications  and according to the Instruc tions for 
Use.  
2.2 Contraindications  
The EndoRotor® should not be used for the primary resection of  lesions or for tissues intended 
for biopsy.  
2.3 Device Use in Clinical Study  
Devices will be used in the study whenever an Investigator decides to use the EndoRotor® 
System for stan dard of care removal of mucosal /sub-mucosal  tissue in the colon.   
3.[ADDRESS_1215804] -market 510(k)  study to collect data in support of the 
safety and performance of th e Interscope EndoRotor® Endoscopic Mucosal Resection System. 
The study will demonstrate that EndoRotor® resections are safe and effective  and support market 
adoption efforts .   
3.1.1 Study Design  
This study has been designed as a prospective, non -randomized, mu lti-center, observational 
study for the treatment of subjects with the need for resection of  recurrent,  flat or sessile  
dysplastic/adenomatous rectal/colonic mucosa  where EndoRotor is the primary resection 
modality.  
3.1.2 Enrollment  
Total enrollment is 60 evaluable subjects at up to 15 clinical sites in the [LOCATION_002] and  
Europe.  Each site may enroll a minim um of one (1) subject and a maximum of 8 subjects until a 
maximum of 60 evaluable subjects are enrolled.  
3.1.3 Study Population  
Adult (>18 years  to ≤85 yea rs) subjects who have at least one  recurrent  flat or sessile  rectal/colon 
mucosal polyp up to  6 cm in dia meter and/or length .  
3.2 Study Duration & Follow -Up 
It is anticipated that the study will begin enrollment in June 2019 .  Enrollment is e xpected to 
continue until December 2019 .  Study subjects shall return for clinic visits in 90 days (+/- 14 
days) post -procedure; data from these visits shall be collected. Primary and other endpoints will 
be assessed.  All subjects will be treated p er this protocol, the Instructions for Use, and as per 
standard of care, as indicated.  The last follow -up visit is expected to b e completed by [CONTACT_11711] 
[ADDRESS_1215805]’s 90 -day (+/ - 14 days) follow -up visit.  The study is complet e follow ing 
the collection of all study data and all final site visits have been completed in June 2020.   
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215806] POPULATION  
4.1 Primary Endpoints  
Primary Effectiveness Endpoint (Performance) : 
Technical Success, defined as th e ability of the EndoRotor device to resect recurrent  flat or 
sessile  colorectal lesions without concomitant  use of other resection modalities for mucosectomy  
and no definitely or probably device -related serious adverse events (SAEs) throughout the 90 -
day follow -up period.  
 
Primary Safety Endpoint :  
Assessment of Serious Adverse Events (incidence, relationship to device and severity) at index 
procedure and at [ADDRESS_1215807] of other secondary endpoi nts to be explored:  
1. Completeness, in percentage, of resection based on endoscopy film and/or 
photographs in addition to diagnostic assessment of specimen by [CONTACT_870759].  
2. Presence of colon stenosis based on endoscopy film and/or photo graphs.  
3. Rate of persistence of disease at the location of resection at 90 days.  
4. Histologic assessment of the diagnostic value of the collected specimens.  
   
4.3 Inclusion Criteria  
Subjects are required to meet ALL  the following inclusion criteria in or der to be included in this 
clinical study:  
1. Subjects aged ≥18 to ≤ [ADDRESS_1215808] one recurrent flat or sessile  colorectal lesion up to 6 cm in diameter and/or length . 
3. Presence of lesion where the EndoRotor® may be used to resect recurrent neoplasia .  
4. Favorable anatomy that allows the investigat or to access the lesion.  
5. Subject is able and willing to comply with site standard medical follow -up, including a [ADDRESS_1215809] has been informed of the nature of the study, agrees to participate and has signed 
the consent form. 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 21 of 44 4.4 Exclusio n Criteria  
Subjects are required to meet NONE  of the following exclusion criteria to be included in this 
clinical study:  
1. Inability to give informed consent.  
2. Subject age is ˂18 or >85 years of age.  
3. Presence of a lesion that represents cancer or has a high chance of harboring  submucosal  
invasive cancer.  
4. Presence of synchronous lesions intended for resection that would necessitate use of a 
concomitant resection m odality   
5. Medical reasons the procedure cannot be performed (i.e. labile blood pressure, 
anticoagulation laboratory levels that are too high and risk excessive bleeding,  systemic 
infection  etc.) 
6. Active antiplatelet therapy (Plavix®, 325mg aspi[INVESTIGATOR_119457] , etc.) where subject cannot be 
off treatment for at least [ADDRESS_1215810] at an 
unacceptable surgical risk (e.g., severe chronic obstructive pulmonary disease, hepatic 
failure, cardiac disease, autoimmune disorders or conditions of severe 
immunosuppression).  
10. Any clinical evidence that  the investig ator feels would place the subject at increased risk 
with the deployment of the device.  
11. Subject is participating in another study of a device, medication, biologic, or other agent 
within [ADDRESS_1215811] Screening  
All subjects presenting to the institution who are scheduled to undergo flexible interventional 
colonoscopy for colon polyps will be informed of the study and offered enr ollment if they meet 
the inclusion/exclusi on criteria.  
A member of the study team shall perform a preliminary evaluation of the potential participant’s 
medical history and previously performed examinations to assess for initial eligibility.  If the 
subject  is willing to participate in the study, a written consent will be obtained.  All subjects that 
have consented to participate in the study will be entered into the Enrollment / Screening Log.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215812] that fails the screening process after providing consent will be considered a screen 
failure; the reason for failing the screen will be recorded on the log.  
5.[ADDRESS_1215813] Enrollment and Withdrawal  
All subjects requiring interventional colo noscopy for colon polyps are potential study candidates 
and will be screened for eligibility.   Every effort will be made to ensure eligibility of the 
participants prior to study pro cedure.   Actual enrollment in the study occurs at the time of 
informed cons ent.   
Subjects who do not meet all inclusion / exclusion criteria (e.g., including inability to reach the 
target area or colon anatomy not conducive to tissue resection) will be co nsidered a screen 
failure and will not be followed in the study (no data wi ll be collected on these subjects).  
Subjects in whom the Interscope EndoRotor® is inserted into the colon and resection is 
attempted, but the procedure is aborted without resection  of tissue , will be followed through 
discharge for safety.  At discharge, t he subject will be assessed for safety only and the subject 
will be allowed to exit the study.  
 
Subjects may withdraw at any time from the clinical study without jeopardy or prejudi ce.  If a 
subject prematurely terminates from the study, the reason for stu dy termination will be recorded 
and the results will be tabulated by [CONTACT_870760].  If termination is the 
result of an adverse event or death, an Adverse Eve nt Form will also be completed.  Subjects 
who withdraw consent after treatm ent will have their data evaluated until the time of their 
withdrawal.  
 
The Investigator should follow all unresolved serious adverse events until the events are 
resolved, the subje ct is lost to follow -up, the subject has withdrawn consent, or the adverse event 
is otherwise explained.  
 
All reasonable efforts will be made to obtain complete data for all subjects; however, missing 
medical observations will occur due to loss to follow -up, withdrawal, or non -adherence with 
required assessments.  If a subject cannot be located, they will be considered lost to follow -up.  If 
they are contact[CONTACT_870761], they will be considered withdrawals.  Dat a collected up to the time of lost to follow -up, 
and withdrawal  of consent  will be maintained in the study database and used for analysis 
purposes, as appropriate. These subjects will not be replaced.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 23 of 44  
Subjects who are enrolled and treated, but who are later discovered to not meet all of the study  
eligibility  criteria will remain in the study and follow -up data will be collected.  A protocol 
deviation will be completed for study subjects who are found to be ineligible after enrol lment.  
5.4 Anticipate d Total Enrollment  
It is anticipated that sixty  (60) evaluable patients will be enrolled. Loss to follow -up is 
anticipated to be no more than 10%.     
5.[ADDRESS_1215814] within 1 day before  the study procedure is required for women of 
childbearing potential.  
 
The following baseline evaluat ions will be assessed and recorded on all patients who provide 
writte n informed consent:  
• Demographic information  
• Medical and surgical history, including risk factors  
• Pregnancy test results (completed within 1 day before the study procedure )  
• Physical exa mination  
o Vital signs  
o Height and weight  
o Target review of symptoms  
• Assessment against I/E criteria  
5.6.[ADDRESS_1215815]’s demographic information and relevant medical history will be documented in the 
subject’s sou rce medical record and on the appropriate case report form (CRF).  T his will include 
the subject’s:  
• Age 
• Gender  
• Height  
• Weight  
• Race and Ethnicity Information  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 24 of 44 • Relevant medical history  
• Physical Examination  
5.7 Index Procedure  
All patients will receive the EndoRot or® treatment following the technique described by 
[CONTACT_695731]’s Instructions for Use .   
The mucosal resections are performed during standard flexible colonoscopy  procedures.  All 
medications given, pre - and post -procedure precautions and follow -up assessme nts are part of 
routine standard of care.  This protocol concerns itself with the actual removal of the mucosal 
lesion once the abnormal area is identified using the colonoscope.  
• Patients will be prepped in the usual manner for lower GI endoscopy prior to their 
interventional visit.   
• The procedures will be performed with either Propofol sedation or under general 
anesthesia.  
• When a mucosal lesion is found, the EndoRotor® system will be prepared by [CONTACT_870762]® catheter, foot pedal and the calib rated suction to the Control Unit, ensuring 
there is a filter in the collection unit (specimen trap), and then priming the catheter with 
0.9% normal saline.     
• Lesions will be injected  using saline solut ion with dye such as Indigo carmine or 
Methylene Blu e.  Indelible ink (such as SPOT) will be injected into the region of the 
resection to identify the site after resection.  
• The EndoRotor® catheter will be inserted through the working channel of the endosc ope 
until it is in proper cutting position with the cutting surface oriented towards the mucosal 
lesion and the catheter no more than 3cm out of the scope.  The physician will turn the 
motor on by [CONTACT_870763]/she wishes to cut ti ssue.   
• Cutting should be performed while moving the EndoRotor® catheter.  The endoscopi[INVESTIGATOR_870742]/she is not intending to cut 
mucosa and when stopped for more than 1 second while apposed to tissue to not ri sk 
creating a perforation.   
• Various techniques can be used to remove the lesion.  Recurrent , flat or sessile  lesions  
will be attempted to be removed entirely with the EndoRotor® with no other treatment 
modalities .  The physician will utilize the recommend ed technique appropriate to the 
lesion until there is no longer visible evidence of mucosal lesion. The intent of the 
protocol is to complete lesion resection using the EndoRotor as the only treatment 
modality. However, s hould it prove not feasible to comp lete the resection with the 
EndoRotor , the investigator may convert to the use of an alternative resection modality.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 25 of 44 • For synchronous lesion interventions, respective lesion specimens should be isolated an d 
separate ly collected  to avoid confounding results.  
• APC or similar techniques used for hemostasis on a resected lesion is not considered an 
alternative resection modality.  
• Treat with EndoRotor, assess percentage of tissue removed with EndoRotor followed by 
[CONTACT_870764].  
• Photo-document the  region following EndoRotor treatment.  
• If the complete lesion cannot be removed in a single treatment visit, a second  visit can be 
sched uled to complete the removal in advance of the 90 day visit.  
5.7.1 Index Procedure  Details   
Refer to the Ins tructions for Use for a description of the procedure.  The following data will be 
collected on all subjects during the index procedure and prior to discharge on the Index 
Procedure case report form:  
• Summary of symptoms from p hysical examination  
• Endoscopic  imaging study  
• The EndoRotor® achieved  the attempted resection  of the targeted lesion(s) . 
• The EndoRotor® pathological specimens were able to be  interpreted by [CONTACT_870765].  
• The total number  of recurrent lesions treated with the EndoRotor.  
• Time from scope insertion to scope removal.  
• EndoRotor time from resection start to resection end.  
• Adverse event assessment and treatment (i.e. delayed bleeding, presence of 
perforations).  Note:  Typi[INVESTIGATOR_870743] (endoscopic clippi[INVESTIGATOR_007]/mucosal 
apposition) will be taken to close perforations if they are discovered.  
• Ease of use and overall satisfaction with the EndoRotor® System.   
• Identification of technical difficulties and device malfunction, if any.  
• Photographs post -EndoRotor treatment .  
 
Current standard of care does not guara ntee pathology in recurrent lesion procedures  due to the 
difficulty to remove they often are treated with avulsion or A rgon Plasma Coagulati on.  Since the 
EndoRotor retrieves spec imen it can be  sent for histopathological review.  Alth ough the 
EndoRotor is not intended for biopsy in this study pathologist  will also be able to  evaluate 
specimen that would normally  be ablated.  Resected tissue collected in the Specimen Trap will 
be placed in 10% Fo rmalin and sent to the resident pathologist for histological evaluation.  The 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 26 of 44 following steps will be taken for the review and interpretation of the specimens fr om the 
Specimen Trap following the procedure:   
1. The r esident pathologist shall be responsibl e for the preparation of the histology 
slides and the review and interpreta tion of the slides per hospi[INVESTIGATOR_870744].   
2. The prepared speci men will be de -identified per hospi[INVESTIGATOR_870745].  
3. An independent pathologist selected by [CONTACT_870766].  
4. The independent pathologis t will document his/her assessment of the quality of the 
specimens.  
 
5. Results of the independ ent pathologist’s assessment will be documented on the 
Histopathology Log within 30 days  of receiving the specimens and uploaded to the 
Sponsor’s secure web serv er. The table will include site number, patient number,  
date of receipt, date of analysis, the analysis result, and the date the specimen was 
returned to the research c enter.  
 
6. The slides  will be shipped back to the hospi[INVESTIGATOR_870746].  
  
5.8 90-Day Follow -Up (+/- 14 days)  
• Assessment of symptoms and ad verse events  
• Using standard of care endoscopy, record the presence of persistent lesions.  Determine 
% of tissue persistence of EndoRotor cases.  
• Using standard o f care endoscopy, record resec tion-associated stenosis.  
• Assessment of the presence of post pol ypectomy syndrome.  
• Independent quality assessment of pathology specimens by [CONTACT_870767].  
6.0 ADVERSE EVENTS  
Adverse events will be recorded and document ed throughout the duration of the study.  In this 
study, adverse events related to the device o r procedure, serious adverse events and 
Unanticipated  Adver se Device Effects will be recorded . Adverse  event s (AE) unrelated to the 
device will not be docume nted on the CRF.    
 
The Investigator at each participating center is ultimately responsible for rep orting applicable 
adverse events to the Sponsor.   The adverse event case report form (CRF) will be used  to record 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215816] documented visit.   
 
The Sponsor shall review all adverse events for their severity, relation ship to the study device(s) 
and comparative an ticipated safety event rates.  The Sponsor will conduct evaluations of any 
unanticipated device -related event per standard operating procedures.  
6.1 Adverse Event (AE)  
Adverse Events (AEs) are clinical findings th at result in an untoward medical event , uninte nded 
disease or injury, or any untoward clinical signs (including an abnormal laboratory findin g) in 
subjects, users, or other persons, regardless of whether or not it is related to the investigational 
medical device .  Adverse events will be classifi ed as to severity (mild, moderate, severe) , 
Anticipated (anticipated, not anticipated)  and d evice and  procedure relationships . Adverse events 
will further be categorized as either serious or non -serious.   
 
The fol lowing definitions for rating severity of advers e events will be used:  
 
Mild:  Awareness of signs or symptoms, but easily tolerated; are of mino r 
irritant type; causing no loss of time from normal activities; symptoms 
would not require medication or a medi cal evaluation; signs or 
symptoms are transient.  
 
Moderate:   Interferes with the subject’s usual activity and/or requires symptomatic 
treatment.  
 
Severe:   Symptom(s) causing severe discomfort and significant impact of the 
subject’s usual activity and requi res treatment.  
 
AEs or SAEs will also be classifi ed as to their relationship to the device and procedure as 
follows:  
Not Related:    The event i s due to an underlying or concurrent illness  or effect of another 
device,  drug or intervention and is not relate d to the investigational 
device, procedure or gen eral surgery.  
Possible:  The event has a strong temporal relationship to the use of the  
investig ational  device,  procedure or general surgery, and an alternative 
etiology is equally or less  likely.  
Probable:  The event has a strong temporal relationship to th e use of the  
investigational  device,  procedure or general surgery and another etiology 
is unlik ely or significantly less likely.  
Definite:  An event that can only be attributed to the use of the  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 28 of 44 investigation al device,  procedure or general  surgery.  
Not Asse ssable:  The event’s relationship to the use of the investigational device, 
procedure  or general  surgery cannot be  assessed.  
 
For purposes of this study, the following events are not considered adverse events  because they 
are normally expected to occur in c onjunction with endoscopic procedures / post -procedure, or 
are associated with customary, stand ard care of subjects undergoing these procedures:  
• Early post -procedural pain (within [ADDRESS_1215817] -study procedu re) related to the 
procedure or position on proce dure table  
• Post-anesthesia/conscious sedation emesis, nausea, or headache (within [ADDRESS_1215818] -
study procedure)  
• Low grade temperature increase ( 38C/101.4F)  
• Systolic or diastolic blood pressure changes that do not require treatment or intervention  
• Any pre-planned surgical procedures  
 
This listing of events is intended to provide guidance to the  study sites for purposes of adverse 
event reporting.  The Investigator at the study site should utilize his/her  own clinical judgment in 
evaluating adverse expe riences and  may decide that the above events should be reported as 
adverse events.  
6.1.1  Serious Ad verse Event (SAE)  
A serious adverse event (SAE) is defined as an adverse event that : 
• Is life threatening or fatal;  
• Results in permanent impairment of a body structure or function;  
• Results in congenital anomal ies/birth defects  
• Requires or prolongs h ospi[INVESTIGATOR_059]; or  
• Requires medical or surgical intervention to preclude permanent impairment of a body 
function or permanent damage to a body structure.     
 
Any other important medical event that may not result in death, be life threat ening, or require 
hospi[INVESTIGATOR_059], may be considered a serious adverse experience when, based upon appropriate 
medical judgement, the event may jeopardize the subject or may requi re an intervention to 
prevent one of the outcomes listed above.  
Delayed bleed ing and perforatio ns are the most serious adverse events associated with the 
resection of mucosal lesions, regardless of technique employed.  Each requires the physician to 
identi fy it (the source of bleeding or the perforation) and swiftly act in a clinic ally appropriate 
manner to rectify the situation.  Severe bleeding requires finding the source of bleeding and 
either using hemoclips or electrocautery to stop the flow of blood.  Perforations, once identified 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 29 of 44 as such, can be treated using specialized endo scopic clips to ap proximate the edges and eliminate 
the perforation.  Unidentified severe bleeding can result in anemia (decrease in the Hemoglobin 
and Hematocrit blood counts) wi th confusion, lethargy, and irritability, as well as hematemesis 
and hematoch ezia (bloody stool s).  Unidentified colon perforations can result in free air within 
the peritoneum causing compression of vascular structures (vena cava), abdominal distention, 
discomfort and pain, as well as sepsis and decreased cardiac output and death.   Patients need to  
be made aware of the seriousness of not feeling well after resection of tissue and encouraged to 
immediately return to the hospi[INVESTIGATOR_603242].   
 
NOTE:  Planned hospi[INVESTIGATOR_272] a pre -existing condition or a procedure required by t he study 
plan, without serious deterioration in health, is not considered a serious adverse event.   
 
NOTE:  Hospi[INVESTIGATOR_12476] (even if less than 24 hours) to a 
healthcare facility as a result of a precipi[INVESTIGATOR_870747]; to i nclude transfer within 
the hospi[INVESTIGATOR_427807]. Hospi[INVESTIGATOR_12478] a precipi[INVESTIGATOR_2505], clinical adv erse effect (e.g., for a preexisting condition not associated 
with a ne w adverse effect or with  a worsening of the preexisting condition; admission for a 
protocol -specified procedure) is not, in itself, a serious adverse  effect.  
 
6.1.2 Unanticipated Adverse Devi ce Effects ( UADE ) 
If an SAE is determined to be probably or definitely related to the investiga tional device and has 
not been previously anticipated, the clinical finding would further be classified as an 
unanticipated adverse device effect (UADE).  A UADE  is defined as “any serious adverse effect 
on health or safety or any life -threatening problem or death caused by, or associated with, a 
device, if that effect, problem, or death was not p reviously identified in nature, severity, or 
degree of incidence in the investigational plan or application (including a supplementary plan or 
application), or any  other unanticipated serious problem associated with a device that relates to 
the rights, saf ety, or welfare  of subjects.”   
 
All SAE /UADEs  must be reported to  the IRB in accordance with institutional policies.  The 
Investigator will note whether the advers e event was device -related or procedure -related and the 
severity of the event. All SAE /UADE s must be reported to Interscope within 24 hours of 
knowledge of the e vent.  
Any Device Malfunction  and/or Failure  shall be documented in the CRFs.   
 
6.2 Adverse Event Re porting Requirements  
6.2.1 General Reporting Requirements  
For the purposes of thi s study, only device -related and procedure -related serious adverse events, 
including u nanticipated, will be recorded and documented on the Adverse Event CRF throughout 
the duration of the study. The report should include, but not limited to: severity, dura tion, action 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215819] ing condition s and 
relationship of the adverse experience to the study device  and procedure . 
All AE’s should be followed until the event is resolved or judged to be clinically stable. The 
clinical site should plan to provide additional, relevant AE follow -up information to the Sponsor 
upon request.  
6.2.[ADDRESS_1215820] be reported by [CONTACT_737] (or designee) to the Sponsor, 
within 24 hours  of becoming aware  of the event.   
 
The Investigator (or designee) must complete the S erious Adverse Event CRF within seven  (7) 
working days of the initial report .  The minimum required data to be recorded for an SAE 
includes: date of event, type of event, duration of event, severity, seriousness, action tak en, 
outcome and, if appropriate, causality and possib le relationship to the Interscope EndoRoto r® 
System.  In the case of a [LOCATION_003]DE, when possible, the device involved in the failure or 
malfunction is to be returned to the Sponsor for analysis.   
All SAE’s sh ould be followed until the event is resolved or judged to be chro nically stable.  The 
clinical site should plan to provide relevant AE follow -up information to the Sponsor upon 
request .  
 
In the case of serious adverse events, procedure and / or device obs ervations, malfunctions or 
failures  medical record documentation (e.g., procedure notes, operat ive notes, discharge 
summary, relevant progress notes, imaging, or lab studies) must be provided to Interscope or its 
designee.   
 
It is the responsibility of th e Investigator to inform the IRB of serious adverse events as req uired 
by [CONTACT_870768].  Any serious adverse 
device effects and all deaths regardless of cause must also be reported to the IRB per loc al IRB 
requirements, and documentation of the report sent to Inte rscope or its designee.  
 
The S ponsor or its designee will report all applicable serious adverse events and device incidents 
as post -market vigilance reports per FDA Regulations .  The Sponsor will decide whether all of 
the local Investigators need to be informed immediately of an SAE or  SADE, or whether this can 
be postponed until the next regularly scheduled study update.  
 
6.2.3 Treatment Failure  & Device Malfunction  Reporting  
All reported device o bservations , malfunctions or failures of the Interscope EndoRotor® System 
are required to be do cumented in the Case Report Form.  In the event of a suspected observation 
or device problem, the study device shall be returned to the Sponsor for analysis via Interscope’ s 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 31 of 44 Complaint System.  Instructions for returning the study device shall be provided t o the 
Investigato r. 
7.0 RISK/BENEFIT ASSESSM ENT  
The Interscope EndoRotor® System has been cleared under the Pre -Market  program as a 510 (K) 
and certified with the CE  Mark and is approved for commercial use wherever the CE Mark is 
recognized.  The device’s safe ty and performance have been established through extensive 
design verification and validation testing, including prior human use, an d through a detailed risk 
analysis process per 21 CFR Part 803 .  Interscope does not anticipate new risks to be identified 
through this clinical study.  A summary of the benefits and risks identified are provided below.  
The main complications  found to be associated with polypectomy ap pear to be 
bleeding/hemorrhage, perforation, and post -polypectomy syndrome, which are reported to occur 
in 0-10.8%, 0 -2.3%, and 0.14 -3.7% of patients, respectively. Deaths have been reported in only 2 
studies, at a rate of 0.01% and 0.1%. The greatest risk  factor for an adverse event is associated 
with increasing polyp size.  
The EndoRotor® holds the  promise to improve the resection of mucosal -based lesions in the GI 
tract (stomach, small and large intestines) by [CONTACT_870769], quicker a nd 
more comprehensive.  Because of its design, the EndoRotor® suctions in mucosa and then cuts it 
(about 1750  times a minute) to quickly remove mucosal disease.  This quick cutting action 
allows the user to precis ely define the resection margins, allowing all gross visible disease to be 
removed.  User errors tend to increase when fatigue increases.  Reducing the procedure time 
from an hour to several minutes can help to reduce the fatigue associated with mucosal 
resections.  There is the potential that we c ould see a reduction in persistent lesions (meaning 
better initial comprehensive removal of dis ease) when the EndoRotor® is used as the resection 
tool, meaning that in the future the necessity for second -look proc edures could be reduced or 
eliminated, furt her decreasing patient morbidity.  Because the EndoRotor® was engineered to be 
a simple device (it only resects mucosa), most users feel comfortable after a few attempts, 
narrowing the performance gap between an e xpert endoscopic proceduralist and one who is still 
in training.  The ease with which physicians learn to use the EndoRotor® could also re sult in less 
patient morbidity.  
7.1.1 Risk Minimization  
As with any endoscopic procedure, appropriate safety precautions wil l be followed.  In addition, 
this protocol provides additional steps to minimize risk to study subjects.  These include the 
following:  
• Investigator Selection :  The Investigator s in this study are selected based on their 
experience in performing endoscopi c treatment procedures, including resection o f 
mucosal tissue.  
• Investigator Training :  All investigators shall be trained on the use of the EndoRotor® 
to develop a base level of proficiency prior to t he execution of the protocol.   
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 32 of 44 • Subject Screening :  Careful subject selection as per device Instructi ons for Use and per 
study selection criteria.  
• Objection by [CONTACT_870770] :  Minors or those patients who are 
incapacitated and cannot consent for themselves are not included in  this study.  
7.[ADDRESS_1215821] -market 
basis, through device sa fety and performance testing, Investigator training, and thr ough closely 
controlled conditions under this study.   
7.4 Incentives (if applicable)  
Subjects will not be offered any incentives to participate in this study.   
8.[ADDRESS_1215822] deviations, and Ns will be used to s ummarize continuous 
characteristics such as age.  Percentages and counts of subjects exhibiting a characteristic will be 
used to summarize categor ical characteri stics such as gender.  
8.2 Analysis Populations  
Two analysis populations are defined for this protoc ol, Intent to Treat and Per Protocol .  
Intent to Treat Population: All subjects in whom the EndoRotor was used for any resection of a 
lesion. This  includes those  subjects that were either treated with the EndoRotor alone or with 
another adjunctive modality . 
 
Per Protocol (PP): Subset of the Intent to Treat population including those subjects who had 
complete lesion resection with the EndoRotor alone  without any ad junctive modality resection, 
did not have inclusion/exclusion protocol deviations and completed  the 90 day follow up visit. 
The effectiveness analyses will be conducted on the per protocol  population .  
 
Safety  Population :  Defined as all subj ects who were  treated  with the device.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215823] documented recurrent flat or sessile  colorectal 
lesions up to 6 cm in diameter and/or length and are treated with the Interscope device  without 
adjunctive modality .  The analysi s will be con ducted on the percent of lesions with persistent 
disease.  The primary endpoint is:   
 
Technical  Success, defined as the ability of the EndoRotor device to resect recurrent  flat or 
sessile  colorectal lesions  without concomitant use of other resection modali ties for mucosectomy 
and no definitely and probably device -related serious adverse events (SAEs ) throughout the [ADDRESS_1215824]  methods6 if all subjects are treated for one lesion.  In the event that one or 
more subjects are treated for multiple lesions, then a generalized e stimating equ ation with a 
logistic link function will be used to estimate the 95% confidence interval of the  success rate.   
8.5 Safety Analysis  
The safety population will include all subjects  in the Intent to Treat Population  treated with the 
Interscope EndoR otor® device.   Only monitored data, including safety data confirmed by [CONTACT_870771] , will be e ntered into the database for statistical analysis.  All serious 
adverse events will be adjudicated by [CONTACT_870772].  Reports of SAE adjudication will be included in the final 
analy sis and clinical report.  
8.[ADDRESS_1215825] the 95% exact confidence 
interval to be between 0.782 a nd 0.967.  Our goal is to achieve a confidence interval half width 
of our point estimate that is not greater than 0.10.  The proposed sample size of 60 will prov ide a 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215826], wi ll not be imputed.  
 
9.0 INVESTIGATOR RESPONS IBILITIES, RECORDS &  REPORT S  
The Investigators are responsible for signing the Investigator agreement prior to the 
commen cement of the study and for ensuring that this study is conducted accordin g to this 
clinical protocol, the Declaration of Helsinki, US FDA requirements and any o ther local, national 
or IRB requirements that apply to post -market clinical studies at their ce nter.   
 
It is also the Investigator’s responsibility to ensure that all sub -investigators and staff assisting 
with this study have the appropriate qualification s and that they complete training on the study 
device and study procedures, as required to fulf ill their rol es in the study, as well as ensuring 
subject confidentiality is respected.   
9.[ADDRESS_1215827] (IRB)  Approval   
Because this study is colle cting medical data from subjects providing wri tten informed consent, 
the Investigator at each s ite is responsible for securing IRB approval for this study protocol and 
the Informed Consent documents.  The local IRB for e ach specific institution (or Western 
Institutional  Review Board ( WIRB) , as applicable  for central IRB sites ) must review and 
approve  this study protocol and the specific Informed Consent form to be used at that site prior 
to study procedure of the first subject.  The Sponsor must  also review and approve the final 
Informed Consent documents prior to their use.  The Sponsor must receive a copy of any IRB 
correspondence as well as the final approval letter and the final approved Informed Consent  from 
the IRB.  
 
The Investigator or clinical site s taff will not make amendments to this protocol or the Informed 
Consent form without PRIOR  writt en approval from the Sponsor.  All approved amendments 
must then be submitted to the IRB, as a ppropriate for approval.  
9.2 Withdrawal of Approval  
If the Investigato r’s IRB withdraws their approval to conduct this study for any reason, the 
Investigator must  notify the Sponsor as soon as possible, but in no event later than five working 
days after the withdrawal of the approval.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215828] complete and accurate records of the clin ical data 
from this study according to the Good C linical Practice (GCP) requirements.  The Investigator 
and/or study staff under his/her directi on is responsible for accurately recording the clinical data 
for this study and submitting it to the Sponsor in a timely manner .  
9.6 Device Accountability  
The Spons or will ship devices intended for this study to the designated Investigators 
participating in t his study following IRB.  All Investigators will be responsible for providing a 
secure storage loc ation for the devices, supervising device use, and the disposal  and/or return of 
the devices as instructed by [CONTACT_1034].  These devices are the same as the commercial devices 
but will be kept separate for the purposes of this study; therefore, all Invest igators will maintain 
records to document the receipt, use and disposition of all devices received by [CONTACT_870773].  The Sponsor will al so maintain records of all shipments and disposition of the 
devices.  The Sponsor and/or their aut horized CRO will routinely inspect the clinical site 
inventory records for device accountability at the clinical sites participating in this study. At the 
conclusion of the study (study enrollment complete), all remaining study devices will be returned 
to the sponsor.   
9.7 Investigator Reports  
9.7.1 Serious Adverse Events (SAE s) & Unanticipated Adverse 
Device Effects (UADEs)  
The Investigator shall report any SAEs or UAD Es as soon as possible, (e.g., within 24 hours of 
the Investigator beco ming aware of the event) to the Sponsor.  Additionally, SAEs and UADEs 
should be reported to the IRB, as required per their local requirements .  The Adverse Event 
electronic CRF is to b e fully completed with in seven  working days of the event.  The contact 
[CONTACT_870774].  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 36 of 44 9.7.2 Device Performance Issues  
The Investigators shall report to Interscope (and/or desi gnee) any Device P erformance issues 
(e.g., device malfunction or failure) that occur to as soon as possible, e.g., 24 hours of the 
Investigator becoming aware of  the event.  The report may be made via telephone, email or fax.  
The Investigator or study sta ff is to return th e devices per the Instructions for Use for 
investigation via Interscope’s complaint handling system, if applicable.  
9.7.[ADDRESS_1215829] follow -up visit.   
Table 2:  Investig ator Report Submission Summary  
Form/Report  Requi red and Suggested Submission Timeframes  
Enroll ment Notification  Complete Study Entry  CRF within 48 hours  of enrollment .  
CRFs  Complete  within 7 days  of visit completion.  
Procedure Images  Upload to the Spo nsor’s secure web server within 7 working days  
of completion.  Images shall be de -identified pr ior to submission.  
Device malfunction / Failure  Notify Sponsor via email within 48  hours of knowledge. Complete  
CRF within 48 hours of knowledge.  
SAEs & UADEs  Complete CRF within 24 hours  of the Investigator becoming aware 
of the event; submit to the IRB as required or as directed by [CONTACT_429].  
Deviations from the CIP  Complete  CRF within 7 days of knowledge.  
Study Progress Reports  As required by [CONTACT_1201]; sub mit to the IRB as required or as directed 
by [CONTACT_1034].  
Final Report to the IRB Within 3 mon ths of study completion.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215830] -market studies.  Interscope will also ensure 
adherence to the Sponsor general duties as outlined by [CONTACT_870775] . Additionally, Interscope will ensure that qualified moni tors and d esignated 
personnel are monitoring the study according to the pre -determined monitoring plan and that the 
Informed Consent process is followed per each site’s lo cal and national requirements.  
10.1 Selection of Clinical Sites & Investigators  
Interscope  will sele ct qualified clinical sites and Investigators who are experienced with 
endoscopic procedures and resection of the mucosa.  The Investigator must work with a qual ified 
IRB to oversee the rights, safety and welfare of the study participants.  T he clinical si te must also 
have an adequate subject population and the appropriate staffing and equipment to meet the 
requirements of the study protocol and the expected enrol lment time frames.  
10.2 Investigator & Staff Training  
Training of the Investigators an d clinical stu dy staff is the responsibility of the Sponsor and their 
designee.  Training may be conducted during a site initiation visit or appropriate training venues 
if the  investigator has not used the device for commercial cases prior to the study.  
Investigator(s)  have received training in proper device operation.  Investigators and study staff 
will undergo training on the study protocol, safety, compliance, eligibility c riteria, device 
accountability, and proper storage of the equipment and supplies,  prior to part icipating in the 
study.  Training may encompass didactic information regarding the study device and system, as 
well as hands -on practice with the device.  Proced ural technique and experience with the 
Interscope device may be assessed by [CONTACT_870776]/engineerin g personnel.  Observations during the 
cases will also be discussed with the Investigator and study staff.   
10.[ADDRESS_1215831] of the 
ENDOROTOR study. The clinical monitors will follow the Sponsor’s standard operating 
procedure for monitoring and the Monito ring Plan to be written on a risk -based approach for 
this study. The Monitoring P lan will requi re evaluation of compliance with the protocol, GCP 
compliance, FDA regulations, and any specific recommendations made by [CONTACT_779]’s IRB and 
the signed Investigat or and Study Agreements. Periodic phone contacts, site visits, and 
intermittent r emote visits w ill be conducted to ensure that the protocol is being followed. The 
clinical monitor(s) will also verify that the electronic Case Report Forms (eCRFs) are in 
agreement with the source documentation and other  records.  
 
For record verificatio n purposes, the clinical monitor and/or authorized Sponsor representative 
will be provided access to hospi[INVESTIGATOR_1097], original laboratory data, and other records and data 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 38 of 44 as th ey relate to the study and as agreed to with the Investigator prior to the init iation of the 
study.  The Investigator will also make available to the clinical monitor all regulatory documents, 
all CRFs, informed consent documents, source documentation and other relevant records for all 
enrolled subjects at the site.  It is important that the Investi gator and other relevant site personnel 
are available for consultation with the clinical monitors during the monitoring visits and that 
sufficient time is devote d at the site to the monitoring process.  
 
If the Sponsor and/or their authoriz ed representativ e become aware that an Investigator is not 
complying with the study protocol, the Investigator Agreement, the Declaration of Helsinki, 
GCP Guideli nes, FDA Regula tions , applicable privacy standards, or any condition of the stud y 
imposed by [CONTACT_1201], the Spon sor or their authorized representative shall immediately secure 
compliance.  An inability to secure compliance and/or to complete an investigation into the 
facto rs that are inhibiting compliance may result in the Investig ator’s termination from the study 
by [CONTACT_1034].   
 
Study close -out visits will be conducted after the final follow -up visit is completed at each site 
and following the resolution of any outstand ing data discrepancies and adverse events.  A final 
study re port will be generated and submitte d to the Investigator and the appropriate study 
oversight authorities.  Study document retention requirements will be reviewed with each site 
during the close -out visit.  
10.[ADDRESS_1215832] 
access to all study records, including source documents, for inspection and duplication.  In the 
event that an Investigator is contact[CONTACT_426] a  local IRB in relation to this study, the  Investigator 
will notify the Sponsor as soon as possi ble.   
 
The Investigator and/or designees must be available to respond to reasonable requests by 
[CONTACT_336557], CRO and regulatory agency representatives du ring the monitoring and 
inspection proces s.  The Investigator must provide the Sponsor with cop ies of all correspondence 
that may affect the review of the current study (i.e., Inspection Observations) or their 
qualification as an Investigator in clinical s tudies conducted by [CONTACT_1034].  The Spo nsor will 
provide any needed assistance to the clinica l site for regulatory audits.  Confidentiality of study 
patients will be maintained consistently as described in Section 11.4.  
10.5 Records & Record Retention  
The Sp onsor and/or their designated CRO shall m aintain copi[INVESTIGATOR_106152], data, device 
shipmen ts, clinical events (AEs, SAEs ) and supporting documentation and other records and 
reports related to this clinical study on a secure web server.   
 
The Sponsor and clinical sites wil l maintain the study records until two (2) years after the final 
study re port is completed, or longer if required by [CONTACT_5737], national or international regulatory 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215833] presentation and 
publication, such secondary publications shall be delegated to the appropriate principal authors, 
and fin al analyses and manuscript review for all multi -center data and/or single -center 
experience repo rts will require approval from Interscope.  
 
This study will be registered with www.clinicaltrials.gov .  
10.[ADDRESS_1215834] Expenses  
The treated subjects will not be compensated for their time during the study.    
11.0 QUALITY ASSURANCE  & ETHICAL STANDARDS  
The study will be conducted according to the Declaration of Helsinki, Good  Clinical Practice 
Guidelines (GCP), FDA Regulations and any additional IRB requirements and  local and/or 
national requirements th at apply to post -market clinica l studies of medical devices.  As the study 
Sponsor, Interscope, Inc . has the overall responsib ility for the conduct of the study, including the 
assurance that the study is in compliance with these guid elines, standards and requirements.  
11.1 Data Monitoring Co mmittee for Adverse Event Adjudication  
To meet the ethical responsibilities and standards for s tudy subjects, at a minimum, an 
Independent Physician Adjudicator (IPA) will serve as the Data Monitoring C ommittee to the 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 40 of 44 Sponsor.  In order to enhance objectiv ity and reduce the potential for bias, the IPA shall be 
independent of the Sponsor as well as t he study sites / investigators.  
 
The IPA shall serve in the following capacities throughout the course of the study: a) adjudicator 
of all reported serious adve rse events, device -related adverse events, and procedure -related 
adverse events; and b) assesso r for severity and causality of all reviewed events to ensure the 
safety of study subjects.  In addition, t he IPA shall serve to assist the sponsor in reviewing 
technical events (e.g., device malfunctions and reported failures) specifically for reporting w ithin 
the study.  Vigilance assessment and reporting will be completed per the sponsor’s Complaint 
Handling  and Vigilance Reporting systems for determining devic e technical events.   
 
The methodology for performing these responsibilities shall be developed  and outlined in the 
Safety Adjudication Charter. The Safety Adjudication Charter shall include study -defin ed 
stoppi[INVESTIGATOR_004].  Operational provisions shall be es tablished to minimize potential bias (i.e., the 
physician serving as IPA shall be blinded to th e clinical site to the extent possible during adverse 
event review and adjudication). In the case of an SAE  with associated imaging, the IPA may 
review imaging a ssessments to assess the reported event.  The Safety Adjudication Charter shall 
be available up on request.   
11.2 Compliance Monitoring & Study Termination  
The Sponsor reserves the right to terminate a site from the study for any of the following 
reasons:  
• Failu re to obtain Informed Consent  
• Failure to report Serious Adverse Events within 48 hours of knowl edge  
• Loss of or unaccountable device inventory  
• Repeated protocol violations or safety concerns  
• Repeated fai lure to complete Case Report Forms  
• Failure to enroll a n adequate number of subjects  
11.[ADDRESS_1215835] clinical data during this study.  
Investigators are responsible for the accurate completion an d timely submission of the data 
collected during this study.  The Case Report Forms will be complet ed on the Sponsor’s secure 
web server .   
11.[ADDRESS_1215836] participating in this study.  A log will be provided to the investigator 
to enable identification of the patient’s name [CONTACT_870780] 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -[ADDRESS_1215837]’s medical records will be lim ited to authorized personnel of the Sponsor, 
their designa ted monitors, clinical site study staff and authorized regulatory authorities as 
required by [CONTACT_3433] e IRB. Any data that may be published in abstracts or scientific journals and/or 
presented at medica l meetings will reference a unique subject code and will not reveal the 
subject’s identity.  The Sponsor and their representatives will make every reasonabl e effort to 
protect the confidentiality of the subjects participating in the study.  
12.[ADDRESS_1215838] (ADE):  An adverse dev ice effect is defined as any untoward adverse 
event related to the use of an investigational  device or unintended response to a medical device.  
NOTE 1: This definition includes adverse events re sulting from insufficient or inadequate 
Instructions for Use,  deployment, implantation, installation, or operation, or any malfunction 
of the medical device . This definition includes any event resulting from insufficiencies or 
inadequacies in the Instructi ons for Use or the deployment of the device or any event that  is a 
result of user error.  
NOTE 2: This definition includes any event resulting from use error  or from intentional 
misuse of the medical device.  
Anemia :  Decrease from baseline in red blood cell s, hemoglobin, or total blood volume that is 
associated with hemodynamic changes or requires transfusion, or a drop in hematocrit to below 
30%.  Any docum ented anemic event requiring ≥2 units PRBCs will be considered an SAE.  
Bleeding Complication at Index Procedure :  Bleeding is considered an adverse event if 
addit ional measures such as endoscopic salvage methods (i.e. OTSC clippi[INVESTIGATOR_007], hemospray) or 
surgery become necessary.  
 
Death:  (divided into 2 categories)  
A.  Cardiac death  is death due to any of the following:  
1. Acute myocardial infarction.  
2. Cardiac perforation/per icardial tamponade.  
3. Arrhythmia or conduction abnormality.  
4. Stroke within 30 days of the proced ure or stroke suspected of being related to the 
procedure.  
5. Death due to complication of the procedure, including bleeding, vascular repair, 
transfusion reaction, o r by[CONTACT_4897].  
6. Any death for which a cardiac cause cannot be excluded.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 42 of 44 B. Non-cardiac deat h is a death not due to cardiac causes (as defined immediately above).  
Delayed Bleeding:  Bleeding that occurs post -procedure  requiring intervention.  
 
Device Failu re:  A device that is used in accordance with the Instructions for Use, but does not 
perform according to the Instructions for Use and negatively impacts the treatment.   
Device Malfunction: A malfunction of a device is an unexpected change to the device t hat is 
contradictory to the Instructions for Use and may or may not affect device performance .  
Includes damage, stress fracture or other failure as observed at the procedure.  
Infection, systemic: Systemic infection documented by [CONTACT_870777], 
requiring medical treatment to treat and resolve.  
Perforation:   Puncture of the alimentary tract.  
Serious Adverse Event (SAE):  A serious adverse event (SAE) is defined an adverse event that:   
• led to death,  
• led to a serious  deterioratio n in the health of the subject, that either resulted in:  
• a life -threatening illness or injury, or 
• resulted in a permanent impairment of a body structure or a body  function, or  
• required in -patient hospi[INVESTIGATOR_135460] , or 
• resulted in medical or surgical intervention to prevent life -threatening illness or injury  or 
permanent impairment to body structure or a body  function, or,  
• Led to fetal distress, fetal death or a congenital abnormality or birth defe ct.  
NOTE:  Plann ed hospi[INVESTIGATOR_272] a pre -existing condition, or a procedure required by [CONTACT_870778], is not considered a serious adverse event.  
Unanticipated Adverse Device Effect (UADE):  A UADE is an event t hat occurs that has not 
been expected to occur with the device or during the course of the study procedures and  has not 
otherwise been identified as a possible risk in the clinical investigations.   
 
 
 
 
 
 
 
 
 
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 43 of 44  
 
13.0       BIBLIOGRAPHY  
1. Repi[INVESTIGATOR_37180] A Hassan C, Vitetta E, Ferrara E, Ma nes G, Gull oti G et al (2012) Safety of cold 
polypectomy for <10mm polyps at colonoscopy: a pro spective multicenter study.  
Endoscopy 44(1):27 -31. 
2. Bretagne J -F, Manfredi S, Pi[INVESTIGATOR_34413] C, Hamonic S, Durand G, Riou F (2010) Yield of high -
grade dysplasia bas ed on  polyp size  detected at colonoscopy: a series of [ADDRESS_1215839] in a population -based study.  
Dis Colon Rectum 53(3):339 -345. 
3. O’Brien, Michael J, et. al.  Flat Adenomas in the National Polyp Study: Is Th ere 
Increased Risk for High -Grade Dysplasia Initially or During Surveillance?; Clinical 
Gastroenterology and Hepatology: 2004;2:905 –911. 
4. Knabe M, Pohl J, Gerges C et al (2013) Standardized Long -Term Follow -Up After 
Endoscopic Resection of Large, Nonpeduncu lated Colorectal Lesions: A Prospective 
Two-Center Study.  American J of Gastroenterology 2014; 109:183 –189; 
doi:10.1038/ajg.2013.419; published online 17 December 2013  
5. Hollerbach S. Meier P. Wellman A. et al.  The EndoRotor®: endoscopic mucosal 
resection  system for non -thermal and rapid removal of esophageal, gastric, and colonic 
lesions: initial experience in live animals. Endosc Int Open. 2016 Apr;4(4):E475 -9. doi: 
10.1055/s -0042 -105207. Epub 2016 Mar 30.  
6. Clopper, C.; Pearson, E. S. (1934). "The use of confidence or fiducial limits illustrated in 
the case of the binomial". Biometrika. 26: 404 –413. doi:10.1093/biomet/26.4.404.  
CLIN 0001 -US Rev A EndoRotor® Colon Safety and Performance Study  
 
CLIN -0001 -US Rev A Proprietary and Confidential  
Page 44 of 44  PPENDIX 1 – SCHEDULE OF EVEN TS 
 
Assessment  Baseline1 Procedure7 Discharge 90 Days  
(+/- 14 Days)  
Informed Consent  X2    
Medica l History  X    
Physical Examination3  X    
Pregnancy  Test6 X    
Endoscopy  X4 X4  X4 
Procedural Data   X3   
Adverse Event 
Assessment   X X X 
Assessment  of presence 
of colon stenosis  and 
rate of persistence of 
disease at the resection 
location     
X 
Ability to interpret the 
pathology samples 
retrieved during 
resection.[ADDRESS_1215840] of physical exam & procedural data collection needs.  
[ADDRESS_1215841]’s interpretation 
of specimens and quality assessment.  Resident patholo gist’s reports shall be submitted to the Sponsor 
within [ADDRESS_1215842] for female subjects o f child bearing potential within 1 day of procedure. 
    7 Second procedure can be completed if complete resection was not achieved  during initia l procedure   
    
 
 
 
 
 
 
 
 
 
 
 